ผลการติดตามระยะยาวในผู้ป่วยเด็กโรคโลหิตจางธาลัสซีเมียชนิดพึ่งพาเลือด ในโรงพยาบาลพหลพลพยุหเสนา

Pattaraporn  Chumpasak

Authors

Pattaraporn Chumpasak Department of Pediatrics, Phaholpolpayuhasena Hospital, Kanchanaburi 71000

Keywords:

iron overload management, long-term follow-up, children, thalassemia, complications

Abstract

Objectives: To investigate the incidence of long-term complications in pediatric patients with transfusion–dependent thalassemia treated at Phaholpolpayuhasena Hospital

Methods: A retrospective descriptive study was conducted among pediatric patients with transfusion-dependent thalassemia treated at Phaholpolpayuhasena Hospital between January 2020 and June 2024, involving 68 patients with follow-up periods ranging from 1 year to 4 years. Data were collected from medical records and analyzed using descriptive statistics.

Results: The mean age of patients receiving last services was 9.0±3.5 years. The most common disease type was β–thalassemia/Hemoglobin E disease (85.3%). Most patients received blood transfusions every 3-4 weeks (82.3%). Iron overload was the most frequently detected complication (97.1%), with all patients receiving iron chelation therapy. Other complications found included abnormal liver function (25.0%), abnormal electrocardiogram (12.0%), and developmental problems (4.5%). No transfusion-transmitted infections were detected. Patients showed improved growth after treatment, with the percentage of underweight patients decreasing from 20.6% to 14.7%.

Conclusions: Pediatric transfusion-dependent thalassemia patients at Phaholpolpayuhasena hospital received treatment following the national standard guidelines for pediatric thalassemia care in Thailand. The treatment for iron overload was appropriate, low incidence of severe complications, and improvement in growth parameters.

References

Paiboonsukwong K, Jopang Y, Winichagoon P, Fucharoen S. Thalassemia in Thailand. Hemoglobin. 2022;46(1):53–7. doi:10.1080/03630269.2022.2025824

Taher AT, Musallam KM, Cappellini MD. β–Thalassemias. N Engl J Med. 2021;384(8):727–43. doi: 10.1056/NEJMra2021838

Cappellini MD, Farmakis D, Porter J, Taher A. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). 4thed. Nicosia: Thalassaemia International Federation; 2021.

Marcon A, Motta I, Taher AT, Cappellini MD. Clinical Complications and Their Management. Hematol Oncol Clin North Am. 2018;32(2):223-36. doi: 10.1016/j.hoc.2017.11.005.

Porter JB, Garbowski MW. Consequences and management of iron overload in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2013;2013(1):447–56. doi: 10.1182/asheducation-2013.1.447

Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–93.

Wood JC. Cardiac complications in thalassemia throughout the lifespan: Victories and challenges. Ann N Y Acad Sci. 2023;1530(1):64-73. doi: 10.1111/nyas.15078.

Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107(9):3436–41. doi: 10.1182/blood-2006-02-002394

Kontoghiorghes CN, Kontoghiorghe GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther. 2016;10:465–81. doi: 10.2147/DDDT.S79458

De Sanctis V, Soliman AT, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M, et al. Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab. 2013;17(1):8–18. doi: 10.4103/2230-8210.107808

Shams S, Haghi Ashtiani MT, Monajemzadeh M, Koochakzadeh L, Irani H, Jafari F, et al. Evaluation of serum insulin, glucose, lipid profile, and liver function in β–thalassemia major patients and their correlation with iron overload. Laboratory Medicine. 2010;41(8):486–9. doi: 10.1309/LMS0EOOUZSII2BNE

Roth C, Pekrun A, Bartz M, Jarry H, Eber S, Lakomek M, Schröter W. Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr. 1997 Oct;156(10):777-83. doi: 10.1007/s004310050711